Objectives. Pulmonary arterial hypertension (PAH) is a major cause of morbidity and mortality in adults with systemic autoimmune rheumatic diseases (ARDs). The aim of this study was to determine whether adults with ARDs and PAH on right-sided heart catheterization (ARD-PAH) have increased mortality following lung transplantation compared with those with PAH not due to an ARD.
Introduction
Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are significant causes of morbidity and mortality in adults with systemic autoimmune rheumatic diseases (ARDs) and often coexist [14] . Adults with severe PAH and/or ILD in the setting of an ARD may require lung transplantation for continued survival. However, transplant centres may be hesitant to offer lung transplantation to adults with ARDs because of concern that extrapulmonary involvement of these systemic diseases may reduce post-transplant survival. We have previously shown that adults with SSc-an ARD with a high prevalence of ILD and PAH-have a 48% increased risk of death at 1 year following lung transplantation compared with those with non-SSc-related ILD but comparable survival to those with non-SSc-related PAH [5] . Further, among those surviving 1 year, there was no detectable difference in 3 year survival between adults with SSc and those with non-SSc-related ILD, while those with SSc had a decreased risk of death at 3 years compared with those with non-SSc-related PAH [5] . Another recent retrospective review of the United Network for Organ Sharing (UNOS) dataset found that adults with non-SSc ARDs had similar survival compared with those with idiopathic pulmonary fibrosis following lung transplantation, but excluded those with non-SSc ARDs who had PAH [6] . It is unknown, therefore, whether the presence of an ARD in an individual with PAH affects postlung transplant mortality. Thus the purpose of this study was to compare the survival of adults with ARDs and PAH (ARD-PAH) to those with PAH not due to an ARD following lung transplantation.
Methods

Participants
We performed a retrospective cohort study of adults with PAH who underwent double or single lung transplantation in the USA between 4 May 2005 (the date of implementation of the lung allocation score [LAS] system [7] ) and 9 March 2015. UNOS, a non-profit organization that records data on all solid organ transplants performed in the USA since 1987, provided the data. Subjects were included if they were at least 18 years of age at the time of transplantation, underwent a double or single lung transplantation during the study period, had a diagnosis of PAH or an ARD (SSc, RA, SLE, MCTD, DM, PM, SS, granulomatosis with polyangiitis, UCTD or unspecified connective tissue disease) with a mean pulmonary artery pressure 545 mmHg on pre-transplant right-sided heart catheterization and were transplanted at a centre that has performed at least one lung transplant for an ARD during the study period. Subjects were excluded if they had received a heartlung transplant, if they received a lung transplant from a living donor or if they had missing data on diagnosis. This study was approved by the Columbia University Institutional Review Board.
Data source
Recipient data, including clinical information, demographics and anthropometrics, were collected by clinical transplant personnel using the UNOS Adult Thoracic Lung Transplant Recipient Registration Worksheet (https:// www.transplantpro.org/wp-content/uploads/sites/3/ Adult_TRR_Lung.pdf). All data were supplied by UNOS via a Standard Transplant Analysis and Research file based on Organ Procurement and Transplantation Network data as of 9 September 2016, accompanied by a coded transplant centre identifier.
Statistical analysis
Our primary outcome was survival time after lung transplantation. To examine the association between a diagnosis of ARD-PAH and survival time after lung transplantation, we modelled diagnosis (ARD-PAH) as the independent binary variable of interest in Cox regression models where survival time censored on 9 September 2016 was the dependent variable. We initially estimated hazard ratios (HRs) for death post-transplant for adults with ARD-PAH compared with adults with PAH in a Cox model without adjustment for additional independent variables. We then constructed a stratified Cox model adjusting for age, sex, LAS (a value that ranges from 0 to 100, with higher scores indicating a higher priority for transplantation [7] ), corticosteroid use and forced vital capacity (FVC). Our adjusted model included strata for mechanical ventilation at the time of transplant and transplant year, thereby allowing us to control for confounding by these variables. We used multiple imputation by chained equations to account for missing covariate data [810] . Fewer than 5% of participants had any missing data. We examined the assumption of proportional hazards using Schoenfeld residuals. A KaplanMeier survival curve was generated. A twosided log-rank test with an overall sample size of 315 subjects (222 in the PAH group and 93 in the ARD-PAH group) achieves 80% power at a 0.05 significance level to detect an HR of 1.4 when the proportion surviving in the PAH group is 0.50 [11, 12] . All analyses were performed using STATA version 13.0 (StataCorp, College Station, TX, USA).
Results
A total of 315 adults underwent lung transplantation during the study period and met inclusion criteria: 93 with ARD-PAH [43 with PAH as the diagnosis at transplantation, 38 with ILD as the diagnosis at transplantation (albeit with a mean pulmonary artery pressure 545 mmHg) and 12 whose primary indication for transplantation could not be determined] and 222 with PAH not due to an ARD (PAH group). Subjects in the ARD-PAH group were older than those in the PAH group (Table 1) . A similar proportion in each group was female. A greater proportion of participants in the ARD-PAH group were black than in the PAH group. The LAS was higher in the ARD-PAH group than in the PAH group. A greater percentage of adults with ARD-PAH were receiving corticosteroids than those with PAH, while a greater percentage of those with PAH were receiving an intravenous prostacyclin analogue than those with ARD-PAH. The percent predicted FVC was lower in the ARD-PAH group. Mean and systolic pulmonary artery pressures were higher in the PAH group than in the ARD-PAH group, however, a similar proportion in each group was receiving extracorporeal membrane oxygenation. A greater proportion of those with ARD-PAH was receiving mechanical ventilation while a similar proportion in each group underwent bilateral lung transplantation (Table 1) .
The unadjusted mortality rate following lung transplantation was 12.85/100 person-years among adults with ARD-PAH and 12.41/100 person-years among adults with PAH. See supplementary Table S1, available at Rheumatology online for a summary of causes of death. We did not detect a difference in the unadjusted mortality rate between adults with ARD-PAH and those with PAH [HR 1.02 (95% CI 0.70, 1.48); Table 1 and Fig. 1 ]. We also did not detect a difference in the multivariable-adjusted mortality rate between adults with ARD-PAH and those with PAH [HR 0.75 (95% CI 0.47, 1.19); Table 1 ].
Discussion
We found that adults with PAH in the setting of an ARD undergoing lung transplantation in the USA since implementation of the LAS system had a similar unadjusted and multivariable-adjusted risk of death compared with those with PAH when controlling for important potential confounders such as FVC, LAS and corticosteroid use. Our findings suggest that the presence of an ARD does not contribute to post-transplant mortality in adults with PAH.
It is known, from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management, that PAH in the setting of an ARD predicts poor transplant-free survival [13] . Therefore, those with ARD-PAH comprise a group in which lung transplantation may be particularly beneficial. Our findings provide support for offering lung transplantation to carefully selected candidates with ARD-PAH.
There are some limitations of this study. Because the diagnoses captured by UNOS are coded by clinical transplant personnel at each transplant centre, it is possible that some adults with ARD-PAH were misclassified as PAH. Some subjects in the ARD-PAH group had restrictive lung disease in addition to PAH, as evidenced by a median FVC of 54% predicted. Some subjects with SSc in the ARD-PAH group were also analysed as part of the SSc Lung transplantation in autoimmune diseases group in our previous study [5] . Participants with ARD-PAH who received lung transplantation underwent rigorous selection processes at their respective transplant centres prior to listing. Thus the outcomes reported in this article are those from carefully selected candidates and therefore might not be generalizable to all adults with ARD-PAH. Finally, UNOS does not capture full clinical or serologic data on ARDs, such as the use of immunosuppressant medications other than corticosteroids, the presence of extrapulmonary manifestations or the presence of autoantibodies, so we were unable to adjust for these variables in our analyses.
In summary, the presence of an ARD in adults with PAH does not lead to increased mortality following lung transplantation compared with those with only PAH, a widely accepted indication for lung transplantation. 
